The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
14:37
China rejects U.S. pressure following the sanctions law on Russia
14:31
Eurostat: Romania continues to be the EU country with the highest annual inflation rate
14:31
Mark Carney supports Canada’s closer ties with the EU / The prime minister welcomes the proposal for associate membership
14:21
Petrișor Peiu says that Nicușor Dan has been more open to consultations, but AUR will not vote for any government formula that the party is not part of
14:12
Victor Ponta announces his intention to become prime minister during consultations at Cotroceni Palace for the appointment of the new head of government
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
